Mail

MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

22.51

-0.99 (-4.21%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	23.50
Open	23.47
Bid	22.53 x 1400
Ask	22.60 x 800
Day's Range	22.43 - 23.50
52 Week Range	13.03 - 29.79
Volume	733,288
Avg. Volume	1,000,222

Market Cap	7.406B
Beta (3Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-4.95
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	27.61

Trade prices are not sourced from all markets

All

News

Press Releases

Yahoo Finance Video27 days ago
How Pinterest's IPO stacks up to other unicorns
Yahoo Finance's Zack Guzman and Heidi Chung are joined by Arthur Zaczkiewicz, Women’s Wear Daily executive editor, to discuss Pinterest's IPO.
CNBC Videos2 months ago
Cramer: Investors can find a better entry point on these recent IPOs
Jim Cramer breaks down the action behind Yeti's recent moves.
Business Wire5 days ago
Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA. Moderna also announced that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 8, 2019 and, subsequently, host a conference call to discuss these results and provide a corporate update. Moderna’s Science Day will feature presentations from Stephen Hoge M.D., president and Melissa Moore Ph.D., chief scientific officer of Moderna’s mRNA Research Platform with a focus on the Company’s newest advances from its commitment to basic and applied sciences.
Zacks10 days ago
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
Motley Fool11 days ago
3 Biotech Stocks That Doubled After Hitting Bottom in 2018
Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.
CNBC12 days ago
Cramer's lightning round: I promised my kids I wouldn't, but I recommend this stock
Jim Cramer zips through his thoughts on callers' questions about their stock picks of the day.
Zacks12 days ago
Options Traders Expect Huge Moves in Moderna (MRNA) Stock
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Investor's Business Daily16 days ago
Why The Biggest IPO In Biotech History Could Have A 'Disruptive' Impact
Moderna stock popped Friday after an analyst rated it a buy, saying the biotech could launch a "disruptive class of medicines." Moderna is experimenting with messenger RNA in several areas.
Business Wire18 days ago
Moderna to Present at 18th Annual Needham Healthcare Conference
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Moderna’s Chief Medical Officer, will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. ET. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.
Benzinga26 days ago
Jim Cramer Gives His Opinion On Bristol-Myers Squibb, Moderna And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Moderna Inc (NASDAQ: MRNA ). He thinks that its technology is good and he believes it's going to be hard pressed to be independent. ...
American City Business Journalslast month
Cambridge VC Flagship raises $824M for new life science investments
One of Massachusetts’ largest venture capital firms, Flagship Pioneering, has raised $824 million to fund new life science startups, it announced Wednesday.
GuruFocus.comlast month
Moderna Inc (MRNA) Files 10-K for the Fiscal Year Ended on December 31, 2018
Moderna Inc (NASDAQ:MRNA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
Simply Wall St.last month
How Much Of Moderna, Inc. (NASDAQ:MRNA) Do Insiders Own?
If you want to know who really controls Moderna, Inc. (NASDAQ:MRNA), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders,Read More...
Business Wire2 months ago
Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress
Shows Continued Execution Across its Pipeline of Infectious Disease, Immuno-Oncology and Rare Disease Programs
Business Wire2 months ago
Moderna to Present at Upcoming Investor Conferences in March
A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
Business Wire2 months ago
Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for 30 days following the call. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
Business Wire2 months ago
Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of a Phase 1a/b study in Nature Communications showing the potential of mRNA encoding for vascular endothelial growth factor A (VEGF-A) as a regenerative therapeutic. This approach aims to stimulate the growth of new blood vessels, also known as angiogenesis, to improve blood flow in tissues where it is otherwise restricted.
GuruFocus.com2 months ago
Andreas Halvorsen's 5 Largest Stock Buys in 4th Quarter
Viking Global rearranges portfolio at end of losing year, expands tech holdings
TheStreet.com2 months ago
Moderna's Small Base Could Surprise on the Upside
Biotechnology company Moderna Inc. was mentioned during Wednesday night's Lightning Round on Jim Cramer's Mad Money program. Cramer said, "This is a speculative one, but these guys are winners.
Motley Fool2 months ago
Is Moderna a Buy?
The biggest-ever biotech IPO heralds enormous promise for a new class of medicines.
Benzinga2 months ago
The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
American City Business Journals2 months ago
Moderna reports early success in respiratory infection vaccine
In a clinical trial of 124 adult subjects, a single dose of the vaccine was linked to a three- to six-fold increase in virus-fighting antibodies, according to Moderna.
Business Wire2 months ago
Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced topline data from the first planned interim analysis of safety and immunogenicity from its Phase 1 study of mRNA-1653 in healthy adults.
Business Wire2 months ago
Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in healthy adults. This is the first monoclonal antibody encoded by mRNA to be dosed in a human and the first development candidate from the Company’s systemic therapeutics modalities to start clinical testing.